Indianapolis, IN Clinical Trials Report — July 2026

Indianapolis participants should act quickly if they match a study nearing enrollment: 43 recruiting trials are expected to close within the next 90 days, including 8 that accept healthy volunteers. The most common closing-soon areas are prostate cancer, with 3 trials, and pain, cholestatic liver disease, and atopic dermatitis, with 2 each.

Indianapolis currently has 843 recruiting clinical trials across 377 research facilities. Nine trials opened in July, down from 20 in June and 11 in May. None of the new July studies accept healthy volunteers, although 71 recruiting studies in the city are available to healthy participants overall.

Closing windows for Indianapolis patients and volunteers

Enrollment can end before a projected closing date if a study reaches its participant target. People affected by the conditions below should contact research sites soon and ask whether screening is still available:

• Prostate cancer (3 closing-soon trials)
• Pain (2 trials)
• Cholestatic liver disease (2 trials)
• Atopic dermatitis (2 trials)
• Amputation or wound complications (1 trial)
• Cancer more generally (1 trial)
• Alcohol use disorder (1 trial)
• Atrial tachycardia (1 trial)
• Traumatic or surgical amputation (1 trial)
• Bipolar I disorder (1 trial)

Eight of the 43 closing-soon studies accept healthy volunteers. Eligibility may still depend on age, sex, medications, medical history, and the amount of time required for visits. Healthy volunteers who are considering participation should inquire promptly, since no new July opening in Indianapolis is currently listed as accepting healthy participants.

New Phase 2 and Phase 3 studies from major sponsors

July’s new trials cover drug, device, and other study types. Drug trials lead with 5 openings, followed by 3 device studies and 3 classified as other. Several notable late-stage or substantial studies provide opportunities for people with excess weight, COPD, alopecia areata, cystic fibrosis, or phenylketonuria:

• NCT07720271 is Novo Nordisk’s Phase 3 AMAZE 9 study of once-daily zenagamtide tablets for people with excess body weight. The study plans to enroll 950 participants and compares zenagamtide with placebo.
• NCT07684820 is a Phase 2 Expedition Therapeutics study of EXPD-101/FXS7553 in people with COPD. Participants are randomized to study drug or placebo taken once daily for 52 weeks, with planned enrollment of 600 people.
• NCT07733765 is Pfizer’s Phase 3 study of ritlecitinib for moderate alopecia areata. It is seeking young people and adults, including participants aged 12 or older where permitted by local regulators. Planned enrollment is 336.
• NCT07694440 is a Phase 2 Maze Therapeutics study evaluating MZE782 in adults with phenylketonuria. The study plans to enroll 38 participants and will assess safety, tolerability, and efficacy.
• NCT07696338, sponsored by Nicole Hamblett, is the REACT trial examining airway-clearance therapies in people with cystic fibrosis. Its parallel studies evaluate hypertonic saline and dornase alfa, with planned enrollment of 405 participants.

Other new July categories include diabetes, hyperglycemia, diabetic foot ulcers, hypoglycemia, dental implants, and immediate dental implant placement. The sponsor mix includes Novo Nordisk, Pfizer, Maze Therapeutics, Expedition Therapeutics, Capsicure, LLC, Indiana University, and other academic or individual investigators. Four new studies are categorized as industry-sponsored, four as other, and one as network research.

Where Indianapolis has the deepest trial access

Indiana University and its affiliated hospitals dominate the city’s research landscape. Indiana University alone lists 99 recruiting trials, while Riley Hospital for Children lists 63, making the IU system particularly important for pediatric and specialty studies. Cancer research is concentrated at the Indiana University/Melvin and Bren Simon Cancer Center and related comprehensive cancer center listings.

• Indiana University (99 trials)
• Riley Hospital for Children (63 trials)
• Indiana University/Melvin and Bren Simon Cancer Center (40 trials)
• Indiana University School of Medicine (39 trials)
• Indiana University Melvin and Bren Simon Comprehensive Cancer Center (25 trials)
• Saint Catherine Hospital (21 trials)
• Indiana University Health University Hospital (20 trials)
• Research Site (19 trials)
• Community Health Network (19 trials)
• Indiana University Health (19 trials)
• Franciscan Health Indianapolis (16 trials)
• IU Health Methodist Hospital (16 trials)

People seeking cancer studies may want to begin with the Simon Cancer Center listings and other IU-affiliated oncology sites. Riley Hospital for Children is the clearest local starting point for families seeking pediatric research. Community Health Network, Franciscan Health Indianapolis, Saint Catherine Hospital, and IU Health sites broaden access for conditions treated in general hospital and outpatient settings.

Eligibility and healthy-volunteer opportunities

Of the nine trials that opened in July, 3 include children, 7 include older adults, and 1 is male-only. No new study is female-only, and no July opening accepts healthy volunteers. The broader Indianapolis market remains more promising for healthy participants, with 71 recruiting studies currently listed for people without the target conditions.

The July decline in new openings follows monthly totals of 19 in February, 17 in March, 12 in April, 11 in May, and 20 in June. People with eligible conditions, parents considering pediatric research, and healthy volunteers should review screening requirements before contacting sites, especially for studies approaching their enrollment deadlines.

Nearby Indiana options

Participants willing to travel can also search outside Indianapolis. Carmel and Fort Wayne each have 2 recruiting trials, while South Bend has 1. These nearby options may be useful when an Indianapolis study has closed, requires a particular diagnosis, or does not match a participant’s age or treatment history.

As the summer pipeline develops, Indianapolis remains anchored by a large IU-led research network. Checking closing-soon studies first, then expanding to nearby cities when needed, can improve the chance of finding an active trial with a convenient site and suitable eligibility requirements.